Biotech Values

[zipjet]

My recent post and the earlier one are based on the same concept, maximizing profits when introducing a generic. I think both posts are consistent and I stand by them. The recent post reflects the greater understanding of how MNTA and NVS will share the revenue stream.

You are right that I should have described the generic from SNY as an authorized-generic.

ij